Skip to main content
Equibles
BIO logo

BIO · Bio-Rad Laboratories, Inc. · Analyst Estimates

Track BIO — free

Use BIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$372.18 -12.22 (-3.18%) At close · Oct 30 Q2 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.95B
Shares
26.74M
Volume · Oct 30 183.13K Avg daily vol (3M) 254.36K

Analyst Estimates

Compare analyst forecasts for Bio-Rad Laboratories, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-16 23:57 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
8.85
9.45
10.10
3
9.45
9.48
9.48
9.00
0
0
4
4
Revenue
USD
Publication date not stated
2.53B
2.57B
2.59B
3
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
8.75
9.75
10.90
3
9.92
10.03
10.03
9.72
0
0
4
4
Revenue
USD
Publication date not stated
2.53B
2.62B
2.67B
3
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.16
2.23
2.29
2
2.23
2.23
2.23
2.31
3
3
0
0
Revenue
USD
Publication date not stated
647.80M
649.95M
652.10M
2
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
2.74
3.02
3.30
2
3.02
2.91
2.91
2.88
2
2
1
1
Revenue
USD
Publication date not stated
691.60M
695.40M
699.20M
2
 — — — — — — — —
Key facts CIK 12208 CUSIP 090572207 13F (30d) 147 filings 120 filers Visit website Investor relations